Arctic Bioscience - Report Publication Announcement 2024

Arctic Bioscience - Invitation to webcast - HeROPA read-out

With reference to stock exchange release regarding the results from the HeROPA

clinical trial read-out.

Arctic Bioscience will host a webcast tomorrow Wednesday 16[th] of October 2024

at 12:00 CET, to present the results from the HeROPA read-out.

The webcast will be hosted by CEO Christer L. Valderhaug and Medical Director

Runhild Gammelsæter.

Webcast details:

Date: Wednesday 16[th] of October 2024

Time: 12:00 CET

Format: Webcast

Language: English

The presentation can be accessed through the link below:

Link: https://channel.royalcast.com/landingpage/hegnarmedia/20241016_1/

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI assistant